Robert Bissonnette

1 month ago | healio.com | Gabrielle Capaldo |Kristen Dowd |Robert Bissonnette

These cookies are necessary for the website to function and cannot be switched off in our systems. They are usually only set in response to actions made by you which amount to a request for services, such as setting your privacy preferences, logging in or filling in forms. You can set your browser to block or alert you about these cookies, but some parts of the site will not then work. These cookies do not store any personally identifiable information.

1 month ago | dermatologytimes.com | Robert Bissonnette |Heidi Anne Duerr

NewsArticleMarch 12, 2025Author(s):,Bissonnette shared highlights and insights on the icotrokinra data presented at the AAD Annual Meeting.

Oct 4, 2024 | mdedge.com | April Armstrong |Robert Bissonnette |Raj Chovatiya |Tina Bhutani

Psoriasis is a chronic inflammatory disease affecting approximately 8 million adults in the United States and 2% of the global population.1,2 Psoriasis causes pain, itching, and disfigurement and is associated with a physical, psychological, and economic burden that substantially affects health-related quality of life.3-5 Setting treatment goals and treating to target are evidence-based approaches that have been successfully applied to several chronic diseases to improve patient outcomes,...

Feb 7, 2024 | nejm.org | Robert Bissonnette |Andreas Pinter |Laura K. Ferris |Ronald Vender

February 8, 2024N Engl J Med 2024; 390:510-521 DOI: 10.1056/NEJMoa2308713 AbstractThe use of monoclonal antibodies has changed the treatment of several immune-mediated inflammatory diseases, including psoriasis. However, these large proteins must be administered by injection. JNJ-77242113 is a novel, orally administered interleukin-23–receptor antagonist peptide that selectively blocks interleukin-23 signaling and downstream cytokine production.

Nov 20, 2023 | onlinelibrary.wiley.com | Robert Bissonnette |Janet Dubois |Paola Facheris |Ester Del Duca

CCL17 C-C motif chemokine ligand 17 CCL22 C-C motif chemokine ligand 22 CCR4 C-C motif chemokine receptor 4 EASI Eczema Area and Severity Index EOT end of treatment MAD multiple ascending dose MADAD meta-analysis derived atopic dermatitis NL non-lesional SAD single ascending dose SCORAD SCORing Atopic Dermatitis Th T-helper cell 1 INTRODUCTION Atopic dermatitis (AD) is a chronic inflammatory skin disease that is estimated to affect ~15%–20% of children and up to 10% of adults worldwide, with...